Why do you need tdap every pregnancy

Overview

The Tdap vaccine, which protects against tetanus, diphtheria, and pertussis (whooping cough), has become a standard recommendation during pregnancy due to the resurgence of pertussis infections in recent decades. The Advisory Committee on Immunization Practices (ACIP) first recommended Tdap vaccination during pregnancy in 2012, with updated guidelines in 2013 specifically advising vaccination during each pregnancy regardless of previous Tdap history. This recommendation emerged from concerning pertussis outbreaks, including a 2010 California epidemic with over 9,000 cases and 10 infant deaths. Historically, pertussis vaccination began with whole-cell vaccines in the 1940s, transitioning to acellular formulations in the 1990s. The current Tdap vaccine contains reduced quantities of diphtheria and pertussis antigens compared to childhood DTaP vaccines, making it appropriate for adolescents and adults. The pregnancy-specific recommendation represents a significant shift from previous approaches that focused only on vaccinating close contacts of newborns (cocooning strategy), which proved less effective than direct maternal vaccination.

How It Works

The Tdap vaccine works by stimulating the pregnant person's immune system to produce protective antibodies against tetanus, diphtheria, and pertussis bacteria. When administered during the third trimester (optimally between 27-36 weeks), these antibodies actively cross the placenta through a process called transplacental antibody transfer, providing passive immunity to the developing fetus. This transfer occurs most efficiently during the late second and third trimesters as placental development matures. The vaccine contains inactivated toxins (toxoids) from tetanus and diphtheria bacteria, along with purified components of Bordetella pertussis bacteria. After vaccination, maternal B-cells produce immunoglobulin G (IgG) antibodies that recognize these antigens. These IgG antibodies then bind to neonatal Fc receptors on placental cells, facilitating their transport into fetal circulation. The transferred antibodies provide immediate protection after birth, bridging the immunity gap until infants can receive their first DTaP vaccine at 2 months old and develop their own active immunity.

Why It Matters

Maternal Tdap vaccination matters because pertussis remains a serious threat to infants, with approximately 50% of pertussis hospitalizations and 90% of pertussis deaths occurring in babies under 2 months old. Before routine maternal vaccination, the United States experienced periodic pertussis epidemics, with over 48,000 reported cases in 2012 alone. The strategy has proven highly effective, with studies showing vaccinated mothers transfer sufficient antibodies to protect approximately 9 out of 10 newborns. This approach has become particularly crucial as pertussis immunity from childhood vaccination wanes over time, leaving many adults susceptible to infection and transmission. Beyond individual protection, maternal Tdap vaccination contributes to herd immunity, reducing community transmission rates. The practice also protects pregnant people themselves from pertussis complications while preventing vertical transmission during birth.